abiraterone has been researched along with Brain Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calais, G; Cancel, M; Florence, AM; Fromont, G; Laurent, E; Linassier, C; Narciso, B; Pobel, C | 1 |
| Faletrov, Y; Frolova, N; Klopava, V; Kulahava, T; Panada, J; Shkumatov, V | 1 |
2 other study(ies) available for abiraterone and Brain Neoplasms
| Article | Year |
|---|---|
Impact of Novel Hormonal Agents (Abiraterone, Enzalutamide) on the Development of Visceral and/or Brain Metastases in Patients With Bone-metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Androstenes; Benzamides; Brain Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
New 3β-hydroxysteroid-indolamine conjugates: Design, synthesis and inhibition of C6 glioma cell proliferation.
Topics: Androstenes; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Endoplasmic Reticulum Stress; Glioma; Glutathione; Hydroxysteroids; Indoles; Molecular Docking Simulation; Rats; Spectrum Analysis; Steroid 17-alpha-Hydroxylase | 2020 |